CA2378257A1 - Procede permettant d'augmenter l'ecoulement sanguin dans le nerf optique, la retine et la choroide afin de faciliter la preservation de la vue - Google Patents

Procede permettant d'augmenter l'ecoulement sanguin dans le nerf optique, la retine et la choroide afin de faciliter la preservation de la vue Download PDF

Info

Publication number
CA2378257A1
CA2378257A1 CA002378257A CA2378257A CA2378257A1 CA 2378257 A1 CA2378257 A1 CA 2378257A1 CA 002378257 A CA002378257 A CA 002378257A CA 2378257 A CA2378257 A CA 2378257A CA 2378257 A1 CA2378257 A1 CA 2378257A1
Authority
CA
Canada
Prior art keywords
agent
composition
cyclic
patient
gmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002378257A
Other languages
English (en)
Inventor
William E. Sponsel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2378257A1 publication Critical patent/CA2378257A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé permettant d'améliorer la fonction visuelle et d'augmenter le plus possible la santé du nerf optique et de la rétine par augmentation de la vitesse de l'écoulement sanguin. Ce procédé consiste à appliquer une quantité efficace d'une préparation d'un agent augmentant les niveaux de GMP cyclique et les niveaux d'oxyde nitrique ou inhibant la phosphodiestérase.
CA002378257A 1999-08-10 2000-08-10 Procede permettant d'augmenter l'ecoulement sanguin dans le nerf optique, la retine et la choroide afin de faciliter la preservation de la vue Abandoned CA2378257A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14815099P 1999-08-10 1999-08-10
US60/148,150 1999-08-10
PCT/US2000/021929 WO2001010406A2 (fr) 1999-08-10 2000-08-10 Procede permettant d'augmenter l'ecoulement sanguin dans le nerf optique, la retine et la choroide afin de faciliter la preservation de la vue

Publications (1)

Publication Number Publication Date
CA2378257A1 true CA2378257A1 (fr) 2001-02-15

Family

ID=22524518

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002378257A Abandoned CA2378257A1 (fr) 1999-08-10 2000-08-10 Procede permettant d'augmenter l'ecoulement sanguin dans le nerf optique, la retine et la choroide afin de faciliter la preservation de la vue

Country Status (5)

Country Link
EP (1) EP1246605A2 (fr)
JP (1) JP2003506394A (fr)
AU (1) AU779991B2 (fr)
CA (1) CA2378257A1 (fr)
WO (1) WO2001010406A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
EP1093814A1 (fr) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Utilisation du dipyridamole ou du mopidamol dans la fabrication d'un médicament pour le traitement et la prévention des troubles de la microcirculation dépendants de la fibrine
SE0202365D0 (sv) 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
ES2294543T3 (es) 2003-07-09 2008-04-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heal Uso de sales de nitrilo para el tratamiento de afecciones cardiovasculares.
KR20060109947A (ko) * 2003-11-20 2006-10-23 오쎄라 파마슈티걸즈, 인크. 황반 변성 및 다른 안과 질환의 개선
US20090214624A1 (en) * 2004-11-29 2009-08-27 The University Of Akron Topical nitric oxide donor devices and methods for their therapeutic use
US8088773B2 (en) * 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
WO2006125123A2 (fr) 2005-05-19 2006-11-23 University Of Cincinnati Procedes pour le traitement d'infections des voies respiratoires chez un sujet utilisant du nitrite acidifie
JP5162859B2 (ja) * 2005-08-31 2013-03-13 大正製薬株式会社 眼精疲労の予防又は緩和剤
US20120237617A1 (en) * 2009-06-18 2012-09-20 Theravasc Inc. Use of nitrite salts in treating tissue damage
JP5791064B2 (ja) * 2009-07-17 2015-10-07 エア・ウォーター株式会社 医薬用組成物
KR20150032552A (ko) 2012-06-11 2015-03-26 매큐클리어 인코포레이션 치료 제제 및 치료 방법
FR3008618A1 (fr) * 2013-07-19 2015-01-23 Univ Paris Curie Utilisation de composes pour restaurer la reponse a la lumiere des cellules de la retine
EP3250201A4 (fr) * 2015-01-28 2018-08-01 Realinn Life Science Limited Composés pour augmenter l'expression et la translocation nucléaire de ppar et utilisation thérapeutique correspondante
SG11201811160XA (en) 2016-06-21 2019-01-30 Univ Newcastle Treatment for myopia
EP3949958A1 (fr) * 2020-08-04 2022-02-09 Eberhard Karls Universität Tübingen Medizinische Fakultät Composé pour le traitement et la prévention d'une maladie associée à la lipofuscine
EP4154888A1 (fr) * 2021-09-24 2023-03-29 Charité - Universitätsmedizin Berlin Inhibiteur pde5 destiné à être utilisés dans le traitement d'affections médicales associées à un déficit en complexe v mitochondrial
CN114177182A (zh) * 2021-12-25 2022-03-15 三维医疗科技有限公司 枸橼酸西地那非/他达拉非/伐地那非在制备治疗近视药物中的应用
EP4233867B1 (fr) * 2022-02-24 2025-09-03 Nicox SA Inhibiteur de pde5 pour utilisation dans le traitement de la neuropathie optique ischémique antérieure
CN116763763B (zh) * 2022-12-05 2024-08-30 齐鲁制药有限公司 一种司美格鲁肽吸入喷雾剂及其制备方法
WO2024200678A1 (fr) 2023-03-28 2024-10-03 Charité - Universitätsmedizin Berlin Inhibiteur de pde5 destiné à être utilisé dans le traitement d'états médicaux associés à un déficit en complexe iv mitochondrial

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733745A (ja) * 1993-07-19 1995-02-03 Taiho Yakuhin Kogyo Kk ２−ニトロイミダゾール化合物
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
AU6823098A (en) * 1997-02-28 1998-09-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists

Also Published As

Publication number Publication date
WO2001010406A2 (fr) 2001-02-15
WO2001010406A3 (fr) 2002-08-08
AU6536500A (en) 2001-03-05
EP1246605A2 (fr) 2002-10-09
JP2003506394A (ja) 2003-02-18
AU779991B2 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
AU779991B2 (en) Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
US6489335B2 (en) Treatment of ocular disease
US7083803B2 (en) Ocular solutions
US20030018044A1 (en) Treatment of ocular disease
US20050250788A1 (en) Aqueous outflow enhancement with vasodilated aqueous cavity
US20060263409A1 (en) Treatment of ocular disease
US20060228394A1 (en) Ocular solutions
KR101689847B1 (ko) 디플루프레드네이트를 포함하는 황반부종 치료용 점안액
CN112135603A (zh) 包含奈必洛尔的药物组合物
US10973758B2 (en) Methods of eye treatment using therapeutic compositions containing dipyridamole
JP2000506833A (ja) 斑水腫の治療
JP2967523B2 (ja) 眼病用製薬組成物
US7638516B2 (en) Agent for therapeutic treatment of optic nerve diseases and the like
US20030007971A1 (en) Remedies for ophthalmic diseases
WO2000021531A1 (fr) Medicaments pour maladies oculaires
JP2005521681A (ja) 尿素および尿素誘導体を使用した眼科疾患の治療方法
US20030225101A1 (en) Method of treating retinal occlusion with sildenafil
US20240285623A1 (en) Trpa1 channel antagonist compound for use in degenerative retinal diseases
CA2398900A1 (fr) Agents therapeutiques pour troubles ophtalmiques
Fallor et al. Ocular toxicity of experimental intravitreal vitamin E
WO2025049378A1 (fr) Formulations ophtalmologiques de nétarsudil à toxicité réduite
HK40107693A (zh) 用於退行性视网膜疾病的trpa1通道拮抗剂化合物
WO2025135087A1 (fr) Composition pharmaceutique pour prévenir/traiter une complication oculaire dans la maladie chronique du greffon contre l'hôte
WO2022090379A1 (fr) Inhibiteur de no-pde5 destiné à être utilisé dans le traitement de la dégénérescence maculaire liée à l'âge de type sec, de l'atrophie géographique et de la neurodégénérescence associée au glaucome
EA050716B1 (ru) Соединение, принадлежащее к пиразолоновому классу, для применения при дегенеративных заболеваниях сетчатки

Legal Events

Date Code Title Description
FZDE Dead